Belite Bio Inc. ADS/$BLTE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Belite Bio Inc. ADS
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Ticker
$BLTE
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
25
Website
BLTE Metrics
BasicAdvanced
$2.1B
-
-$1.37
-1.48
-
Price and volume
Market cap
$2.1B
Beta
-1.48
52-week high
$74.15
52-week low
$49.00
Average daily volume
61K
Financial strength
Current ratio
25.981
Interest coverage (TTM)
-2,359.25%
Profitability
EBITDA (TTM)
-47.01
Management effectiveness
Return on assets (TTM)
-22.23%
Return on equity (TTM)
-33.43%
Valuation
Price to book
13.38
Price to tangible book (TTM)
13.38
Growth
Earnings per share change (TTM)
20.58%
3-year earnings per share growth (CAGR)
16.72%
Bulls say / Bears say
Belite Bio's lead candidate, Tinlarebant, received Breakthrough Therapy Designation from the FDA for treating Stargardt disease, indicating strong potential for expedited development and approval. (newsheater.com)
The company successfully completed enrollment in its Phase 3 PHOENIX trial for geographic atrophy, demonstrating progress in its clinical pipeline. (simplywall.st)
Analysts have raised their price targets for Belite Bio, with Maxim Group increasing its target to $110, reflecting confidence in the company's growth prospects. (defenseworld.net)
Belite Bio reported a net loss of $14.3 million in Q1 2025, up from $7.9 million in the same period last year, indicating increasing operational expenses. (stocktitan.net)
Leerink Partners reduced their FY2028 EPS estimate for Belite Bio from $4.60 to $4.40, suggesting tempered expectations for long-term profitability. (etfdailynews.com)
The company's reliance on successful clinical trial outcomes for Tinlarebant poses a risk; any setbacks could negatively impact stock performance. (simplywall.st)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Belite Bio Inc. ADS stock?
Belite Bio Inc. ADS (BLTE) has a market cap of $2.1B as of August 01, 2025.
What is the P/E ratio for Belite Bio Inc. ADS stock?
The price to earnings (P/E) ratio for Belite Bio Inc. ADS (BLTE) stock is 0 as of August 01, 2025.
Does Belite Bio Inc. ADS stock pay dividends?
No, Belite Bio Inc. ADS (BLTE) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Belite Bio Inc. ADS dividend payment date?
Belite Bio Inc. ADS (BLTE) stock does not pay dividends to its shareholders.
What is the beta indicator for Belite Bio Inc. ADS?
Belite Bio Inc. ADS (BLTE) has a beta rating of -1.48. This means that it has an inverse relation to market volatility.